XORTX Therapeutics Inc. (NASDAQ:XRTX – Get Free Report) saw a significant increase in short interest in April. As of April 30th, there was short interest totaling 79,644 shares, an increase of 79.0% from the April 15th total of 44,502 shares. Approximately 6.1% of the shares of the company are short sold. Based on an average trading volume of 6,498,507 shares, the days-to-cover ratio is currently 0.0 days.
Analyst Ratings Changes
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of XORTX Therapeutics in a report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.
Read Our Latest Stock Report on XORTX Therapeutics
Institutional Trading of XORTX Therapeutics
XORTX Therapeutics Stock Performance
Shares of XRTX opened at $2.59 on Monday. XORTX Therapeutics has a 12 month low of $1.73 and a 12 month high of $7.05. The stock’s 50 day moving average is $2.32 and its two-hundred day moving average is $2.60. The firm has a market cap of $4.01 million, a P/E ratio of -0.86 and a beta of 0.80.
XORTX Therapeutics (NASDAQ:XRTX – Get Free Report) last issued its quarterly earnings results on Thursday, February 26th. The technology company reported ($0.45) earnings per share (EPS) for the quarter.
About XORTX Therapeutics
Xyratex Ltd (Xyratex) is a provider of data storage technology, including modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex operates in two segments: Networked Storage Solutions (NSS) and Storage Infrastructure (SI). Its NSS products are primarily HDD based data storage subsystems and solutions, which it provides to original equipment manufacturers. Its SI products consist of HDD manufacturing process equipment, which it sells directly to manufacturers of HDDs and their component suppliers.
Recommended Stories
- Five stocks we like better than XORTX Therapeutics
- Datadog Soars, Dynatrace Slumps: Gap Widens in AI Agent Stocks
- As U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” Trade
- Robinhood, SoFi, and Webull Are Telling Very Different Stories
- As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In
Receive News & Ratings for XORTX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XORTX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
